Skip to search formSkip to main contentSkip to account menu

labetuzumab

Known as: monoclonal antibody hMN-14, hMN-14, MAb hMN14 
A humanized monoclonal antibody that recognizes carcinoembryonic antigen.
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Monoclonal, Humanized
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing…
2505 Background: Combination chemotherapies with 5-FU, irinotecan, oxaliplatin, anti-VEGF, and anti-EGFR agents have improved the… 
Highly Cited
2005
Highly Cited
2005
Development of humanized antibodies as cancer therapeutics.
2005
2005
Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody
Purpose: A disadvantage of conventionally radioiodinated monoclonal antibodies (mAb) for cancer therapy is the short retention… 
2005
2005
Radioimmunotherapy for Colorectal Cancer
Monoclonal antibodies, selected for their ability to recognize and bind tumor-specific antigens, are a promising vehicle for… 
Highly Cited
2004
Highly Cited
2004
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
UNLABELLED The aim of this work was to develop reagents and methods potentially useful in PET, using (68)Ga in a 2-step… 
Highly Cited
2003
Highly Cited
2003
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I…
PURPOSE Pharmacokinetics and dosimetry of hMN-14 x m734 bispecific monoclonal antibody (BsMAb) and (131)I-labeled di… 
Highly Cited
2003
Highly Cited
2003
Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
PURPOSE With increasing interest in pretargeting procedures for improving the delivery of radionuclides for cancer imaging and… 
Highly Cited
1997
Highly Cited
1997
Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
UNLABELLED In this study, we examined the factors that may influence tumor dosimetry in the radioimmunotherapy of solid, CEA… 
1995
1995
Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments.
A natural N-linked glycosylation site (Asn-Val-Thr) at amino acid positions 18-20 (Kabat's numbering) was identified in the… 
1995
1995
Bacterial expression of a kemptide fusion protein facilitates 32P labeling of a humanized, anti-carcinoembryonic antigen (hMN-14) antibody fragment.
Despite the potential advantages of 32P over other isotopes for radioimmunotherapy, its development as a therapeutic has been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)